DIASORIN RECEIVES FDA CLEARANCE FOR THE LIAISON BRAHMS PCT II GEN ASSAY TO DETECT SEVERE BACTERIAL INFECTIONS (e.g. Sepsis)

April 5th, 2018 - Saluggia (VC) - DiaSorin (FTSE Italia Mid Cap: DIA) announces that it has received clearance from the US Food and Drug Administration to market the LIAISON BRAHMS PCT II GEN assay for Sepsis’ diagnosis through the quantitative determination of procalcitonin (PCT).

Sepsis is a systemic inflammation caused by uncontrolled bacterial infection. Despite advances in modern medicine, including antibiotics and vaccines, sepsis affects over 26 million people every year in the world and remains the primary cause of death from infection. According to the Centers for Disease Control and Prevention (CDC), in the US more than 1.5 million people develop sepsis and approximately 250,000 die each year. Moreover, hospital costs associated to severe sepsis' treatment are estimated around $20.3 billion annually and much of this cost is attributed to delayed or misdiagnosis.

Clinical evaluations in various specialized fields of medicine have shown PCT produced by severe bacterial infections (e.g. sepsis) to be a good indicator in differentiating sepsis from systemic inflammatory reactions.

Moreover, PCT aids in the diagnosis of inflammatory severity, monitors therapy progression, and antibiotic treatment to patients affected by sepsis.

Carlo Rosa, CEO of DiaSorin Group, commented: “Through the launch of this new test, we further strengthen our positioning in the US diagnostic market, achieving on the time set another important goal of our 2017-2019 plan”.

About DiaSorin Group

Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “Diagnostics Specialist.”

For additional information, please contact:

Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Ines Di Terlizzi
Investor Relator
Tel: +39.0161.487567
ines.diterlizzi@diasorin.it